New combo aims to outsmart resistant prostate cancer
NCT ID NCT07002320
First seen Jan 07, 2026 · Last updated Jun 13, 2026 · Updated 23 times
Summary
This study tests whether adding an experimental drug called SX-682 to the standard drug apalutamide can help men with a tough-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The goal is to find a safe dose that also reduces certain immune cells that help the cancer grow. About 78 men will take part, and researchers will check if the combination shrinks tumors or lowers PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Belfast Health and Social Care Trust
RECRUITINGBelfast, BT9 7AB, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cambridge University Hospitals NHS Foundation Trust
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Oncology Institute of Southern Switzerland
NOT_YET_RECRUITINGBellinzona, CH6500, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
The Royal Marsden NHS Foundation Trust - Drug Development Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.